Low CD4+ T-cell counts in HIV patients receiving effective antiretroviral therapy are associated with CD4+ T-cell activation and senescence but not with lower effector memory T-cell function

Clinical Immunology

Volumn 120, Issue 2, 2006, Pages 163-170

  Fernandez, Sonia ^a,b   Price, Patricia ^a,b   McKinnon, Elizabeth J ^c   Nolan, Richard C ^a   French, Martyn A ^a,b  

^a ROYAL PERTH HOSPITAL   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c MURDOCH UNIVERSITY   (Australia)

Author keywords

Antiretroviral therapy; HIV 1; Immune activation; Interferon ; Senescence; T cell responses

Indexed keywords

ANTIRETROVIRUS AGENT; CD57 ANTIGEN; GAMMA INTERFERON; HLA DR ANTIGEN; KI 67 ANTIGEN; VIRUS RNA;

ADULT; AGED; ARTICLE; CD4 LYMPHOCYTE COUNT; CELL ACTIVATION; CELL FUNCTION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; FLOW CYTOMETRY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MEMORY T LYMPHOCYTE; NONHUMAN; PREDICTION; PRIORITY JOURNAL; SENESCENCE; T LYMPHOCYTE ACTIVATION;

ADULT; AGED; ANTI-HIV AGENTS; BIOLOGICAL MARKERS; CD4-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; FEMALE; HIV INFECTIONS; HUMANS; IMMUNOLOGIC MEMORY; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; ORGAN SIZE; THYMUS GLAND;

EID: 33746085971     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2006.04.570     Document Type: Article

References (28)

1. Piketty C., Weiss L., Thomas F., Mohamed A.S., Belec L., and Kazatchkine M.D. Long-term clinical outcome of human immunodeficiency virus-infected patients with discordant immunologic and virologic responses to a protease inhibitor-containing regimen. J. Infect. Dis. 183 (2001) 1328-1335
2. Kaufmann G.R., Perrin L., Pantaleo G., Opravil M., Furrer H., Telenti A., Hirschel B., Ledergerber B., Vernazza P., Bernasconi E., Rickenbach M., Egger M., Battegay M., and Swiss HIV Cohort Study Group. CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study. Arch. Intern. Med. 163 (2003) 2187-2195
3. Kaufmann G.R., Furrer H., Ledergerber B., Perrin L., Opravil M., Vernazza P., Cavassini M., Bernasconi E., Rickenbach M., Hirschel B., Battegay M., and Swiss HIV Cohort Study. Characteristics, determinants and clinical relevance of CD4 T cell recovery to <500 cells/μl in HIV type 1-infected individuals receiving potent antiretroviral therapy. Clin. Infect. Dis. 41 (2005) 361-372
4. + cell counts after successful virologic suppression. Clin. Infect. Dis. 35 (2002) 1005-1009
5. Teixeira L., Valdez H., McCune J.M., Koup R.A., Badley A.D., Hellerstein M.K., Napolitano L.A., Douek D.C., Mbisa G., Deeks S., Harris J.M., Barbour J.D., Gross B.H., Francis I.R., Halvorsen R., Asaad R., and Lederman M.M. Poor CD4 T cell restoration after suppression of HIV-1 replication may reflect lower thymic function. AIDS 15 (2001) 1749-1756
6. Fernandez S., Nolan R.C., Price P., Krueger R., Wood C., Cameron D., Solomon A., Lewin S.R., and French M.A. Thymic function in severely immunodeficient HIV-1 infected patients receiving stable and effective antiretroviral therapy. AIDS Res. Hum. Retroviruses 22 (2006) 163-170
7. + T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. J. Infect. Dis. 187 (2003) 1534-1543
8. Mildvan D., Bosch R.J., Kim R.S., Spritzler J., Haas D.W., Kuritzkes D., Kagan J., Nokta M., DeGruttola V., Moreno M., and Landay A. Immunophenotypic markers and antiretroviral therapy (IMART): T cell activation and maturation help predict treatment response. J. Infect. Dis. 189 (2004) 1811-1820
9. Benito J.M., Lopez M., Lozano S., Ballesteros C., Martinez P., Gonzalez-Lahoz J., and Soriano V. Differential upregulation of CD38 on different T-cell subsets may influence the ability to reconstitute CD4+ T cells under successful highly active antiretroviral therapy. J. Acquired Immune Defic. Syndr. 38 (2005) 373-381
10. Anthony K.B., Yoder C., Metcalf J.A., DerSimonian R., Orenstein J.M., Stevens R.A., Falloon J., Polis M.A., Lane H.C., and Sereti I. Incomplete CD4 T cell recovery in HIV-1 infection after 12 months of highly active antiretroviral therapy is associated with ongoing increased CD4 T cell activation and turnover. J. Acquired Immune Defic. Syndr. 33 (2003) 125-133
11. + cells in HIV-1-infected patients receiving highly active antiretroviral therapy who have prolonged undetectable plasma viral loads. J. Infect. Dis. 191 (2005) 1670-1679
12. + T-cell differentiation towards senescence in HIV-1 infection. PLOS Biol. 2 (2004) 0173-0185
13. + T cells. Blood 101 (2003) 2711-2720
14. + T-cell subpopulation with memory phenotype in tuberculosis patients. Immunology 111 (2004) 100-106
15. van Baarle D., Tsegaye A., Miedema F., and Akbar A. Significance of senescence for virus-specific memory T cell responses: rapid ageing during chronic stimulation of the immune system. Immunol Lett. 97 (2005) 19-29
16. Keane N.M., Price P., Stone S.F., John M., Murray R.J., and French M.A. Assessment of immune function by lymphoproliferation underestimates lymphocyte functional capacity in HIV patients treated with highly active antiretroviral therapy. AIDS Res. Hum. Retroviruses 16 (2000) 1991-1996
17. Sawhney N., and Hall P.A. Ki67-structure, function and new antibodies. J. Pathol. 168 (1992) 161-162
18. + T cells correlate with plasma human immunodeficiency virus (HIV-1) RNA level in HIV-1 infection. J. Infect. Dis. 178 (1998) 1279-1287
19. + T cells go out of stock. Nat. Immunol. 1 (2000) 285-289
20. Hazenberg M.D., Otto S.A., van Benthem B.H.B., Roos M.T.L., Coutinho R.A., Lange J.M.A., Hamann D., Prins M., and Miedema F. Persistent immune activation in HIV-1 infection is associated with progression to AIDS. AIDS 17 (2003) 1881-1888
21. Almeida C.A., Price P., and French M.A. Immune activation in patients with HIV type 1 and maintaining suppression of viral replication by highly active antiretroviral therapy. AIDS Res. Hum. Retroviruses 18 (2002) 1351-1355
22. + T cell activation. J. Infect. Dis. 192 (2005) 2142-2146
23. Al-Harthi L., Voris J., Patterson B.K., Becker S., Eron J., Smith K.Y., D'Amico R., Mildvan D., Snidow J., Pobiner B., Yau L., and Landay A. Evaluation of the impact of highly active antiretroviral therapy on immune recovery in antiretroviral naïve patients. HIV Med. 5 (2004) 55-65
24. Chun T., Nickle D.C., Justement J.S., Large D., Semerjian A., Curlin M.E., O'Shea M.A., Hallahan C.W., Daucher M., Ward D.J., Moir S., Mullins J.I., Kovacs C., and Fauci A.S. HIV-infected individuals receiving effective antiviral therapy for extended periods of time continually replenish their viral reservoir. J. Clin. Invest. 115 (2005) 3250-3255
25. + T-cell activation and bystander apoptosis induced by human immunodeficiency virus type 1 virions. J. Virol. 79 (2005) 6299-6311
26. + T cells and their association with HIV-1-induced T cell dysfunction. J. Immunol. 175 (2005) 8415-8423
27. + T cells to CD3-mediated apoptosis. Clin. Exp. Immunol. 139 (2005) 268-278
28. +T-cell responses to subcutaneous (sc) recombinant interleukin-2 (rIL-2) after one year. 16th Annual Conference of the Australasian Society for HIV Medicine, Canberra, Australia.